Salesforce Lands Novartis for Five-Year Global Agentforce Rollout as Analysts Reiterate Buys

Overview

• Novartis will deploy Agentforce 360 for Life Sciences globally over the next five years to connect patient and healthcare professional experiences.
• The company aims to unify engagement across marketing, sales, patient services, medical affairs, and market access, extending earlier investments in Salesforce platforms.
• BTIG initiated coverage with a Buy rating and a $335 price target on December 17, and Mizuho reiterated Buy with a $340 target on December 16.
• Jim Cramer said he remains constructive on Salesforce, citing the need for Agentforce to keep delivering and noting the stock trades around 20 times next year’s earnings estimates.
• Cramer also said Agentforce has reached a $500 million run rate and could redefine Salesforce within 12 to 18 months, while flagging concerns that some customers might build their own AI tools.